Importer of Controlled Substances, Notice of Registration: Hospira Inc., 15975 [2013-05794]

Download as PDF Federal Register / Vol. 78, No. 49 / Wednesday, March 13, 2013 / Notices This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, 40 FR 43745–46, all applicants for registration to import a basic class of any controlled substances in schedules I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied. Dated: March 7, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration mstockstill on DSK4VPTVN1PROD with NOTICES Importer of Controlled Substances, Notice of Registration: Hospira Inc. By Notice dated December 14, 2012, and published in the Federal Register on December 21, 2012, 77 FR 75670, Hospira Inc., 1776 North Centennial Drive, McPherson, Kansas 67460–1247, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of Remifentanil (9739), a basic class of controlled substance listed in schedule II. The company plans to import Remifentanil for use in dosage form manufacturing. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a), and determined that the registration of Hospira Inc. to import the basic class of controlled substance is consistent with the public interest, and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Hospira Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 17:11 Mar 12, 2013 Jkt 229001 Dated: March 7, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2013–05794 Filed 3–12–13; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances, Notice of Registration; Johnson Matthey, Inc., Pharmaceuticals Materials By Notice dated November 1, 2012, and published in the Federal Register on November 9, 2012, 77 FR 67397, Johnson Matthey, Inc., Pharmaceuticals Materials, 900 River Road, Conshohocken, Pennsylvania 19428, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: [FR Doc. 2013–05793 Filed 3–12–13; 8:45 am] VerDate Mar<15>2010 CFR 1301.34, the above named company is granted registration as an importer of the basic class of controlled substance listed. Drug Schedule Gamma Hydroxybutyric Acid (2010). Amphetamine (1100) .................... Methylphenidate (1724) ................ Codeine (9050) ............................. Oxycodone (9143) ........................ Diphenoxylate (9170) ................... Hydrocodone (9193) ..................... Meperidine (9230) ........................ Methadone (9250) ........................ Methadone intermediate (9254) ... Morphine (9300) ........................... Thebaine (9333) ........................... I II II II II II II II II II II II The company plans to manufacture the listed controlled substances in bulk for distribution and sale to its customers. The Thebaine (9333) will also be used to manufacture other controlled substances for sale in bulk to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Johnson Matthey Inc., Pharmaceuticals Materials to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Johnson Matthey Inc., Pharmaceuticals Materials to ensure that the company’s registration is consistent with the public interest. The investigation has included PO 00000 Frm 00048 Fmt 4703 Sfmt 9990 15975 inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: February 27, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2013–05799 Filed 3–12–13; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF LABOR Office of the Secretary Agency Information Collection Activities; Submission for OMB Review; Comment Request; Job Clubs Study ACTION: Notice; correction. The Department of Labor published a document in the Federal Register of February 26, 2013, concerning request for comments on site visits to job clubs. The document contained incorrect dates. SUMMARY: FOR FURTHER INFORMATION CONTACT: Contact Ben Seigel by telephone at 202– 693–6032 (this is not a toll-free number) or by email at CFBNP@dol.gov. Correction In the Federal Register of February 26, 2013, in FR Doc. 2013–04391, on page 13086, in the second column, correct the DATES caption to read: Written comments must be submitted to the office listed in the addressee section on or before April 27, 2013. DATES: Signed at Washington, DC, this 5th day of March, 2013. Irasema Garza, Acting Assistant Secretary for Policy, U.S. Department of Labor . [FR Doc. 2013–05775 Filed 3–12–13; 8:45 am] BILLING CODE P E:\FR\FM\13MRN1.SGM 13MRN1

Agencies

[Federal Register Volume 78, Number 49 (Wednesday, March 13, 2013)]
[Notices]
[Page 15975]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-05794]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances, Notice of Registration: 
Hospira Inc.

    By Notice dated December 14, 2012, and published in the Federal 
Register on December 21, 2012, 77 FR 75670, Hospira Inc., 1776 North 
Centennial Drive, McPherson, Kansas 67460-1247, made application by 
renewal to the Drug Enforcement Administration (DEA) to be registered 
as an importer of Remifentanil (9739), a basic class of controlled 
substance listed in schedule II.
    The company plans to import Remifentanil for use in dosage form 
manufacturing.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and 952(a), and determined that the 
registration of Hospira Inc. to import the basic class of controlled 
substance is consistent with the public interest, and with United 
States obligations under international treaties, conventions, or 
protocols in effect on May 1, 1971, at this time. DEA has investigated 
Hospira Inc. to ensure that the company's registration is consistent 
with the public interest. The investigation has included inspection and 
testing of the company's physical security systems, verification of the 
company's compliance with state and local laws, and a review of the 
company's background and history. Therefore, pursuant to 21 U.S.C. 
952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above 
named company is granted registration as an importer of the basic class 
of controlled substance listed.

    Dated: March 7, 2013.
Joseph T. Rannazzisi,
 Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2013-05794 Filed 3-12-13; 8:45 am]
BILLING CODE 4410-09-P